arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Ionis Pharmaceuticals, Inc.

IONS Health Care Biotechnology: Pharmaceutical Preparations
$55.90
▼ -3.8% Today
as of Sep 4, 16:50 ET
Last 30 days +5.05% Jul 28 → Sep 04
$50.83 $54.25 $57.67 $61.09 $64.51 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$58.36
High
$58.96
Low
$57.78
Volume
$2M
Avg Vol
$2M
Mkt Cap
$9.1B
P/E (TTM)
—
Beta
—
52w High
$86.74
52w Low
$50.01
Div Yield
—
Shares Out
$166M

Recent Press Releases & News last 60 days · 25 items

Sep 5 · 12:51 BioPharma Dive
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
Sep 4 · 22:52 Stocktwits
NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?
Sep 4 · 21:25 Investor's Business Daily
Novartis, Ionis Tumble On Surprise Flop For Heart Drug
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$50
$87
16% of range
Avg surprise (last 2)
+378.1%
Avg reaction (last 1)
+3.0%
100% positive
Latest IV / EM
61%
EM ±9.5% · $58 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.16$-0.69$-0.23$0.24$0.70 Actual $-0.87Actual $-0.60Actual $-1.03Actual $-0.98Actual $-0.45Actual $-0.95Actual $-0.93Est $-1.16Actual $0.70Est $-0.11Actual $-0.80Actual $-0.56Actual $-0.69 MarJunSepMarJunSepMar/2025Jun/2025SepMarJun
Revenue vs Net Income Revenue Net income
$-147M$8M$164M$319M$475M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.69 — — — — financials
Tue Mar 31, 2026Mar 2026 $-0.56 — — — — financials
Tue Sep 30, 2025Sep 2025 $-0.80 — — — — financials
Wed Jul 30, 2025Jun/2025 $0.70 $-0.11 +736.4% — — earnings
Wed Apr 30, 2025Mar/2025 $-0.93 $-1.16 +19.8% — +3.0% earnings
Mon Sep 30, 2024Sep 2024 $-0.95 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.45 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.98 — — — — financials
Sat Sep 30, 2023Sep 2023 $-1.03 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.60 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.87 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$268M$246M—$157M$452M$132M—$134M
Cost of revenue$3M$3M—$2M$4M$1M—$1M
Gross profit————————
Operating income$-102M$-117M—$-160M$140M$-147M—$-149M
Net income$-115M$-93M—$-129M$124M$-147M—$-140M
EPS (diluted)$-0.69$-0.56—$-0.80$0.70$-0.93—$-0.95

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$350M$173M$372M$338M$297M$264M$242M$335M
Inventory$51M$6M$10M$10M$8M$12M$13M$28M
Total current assets$2.49B$2.94B$2.99B$2.52B$2.58B$2.42B$2.62B$2.71B
Total assets$2.99B$3.45B$3.52B$3.03B$2.99B$2.81B$3.00B$3.08B
Long-term debt————————
Total liabilities$2.55B$2.96B$3.03B$2.42B$2.35B$2.34B$2.42B$2.42B
Total equity$440M$491M$489M$618M$632M$476M$588M$662M

Implied volatility — last 90 days

28%52%76%100%124% Jun 07 — IV 42% · EM ±5.8%Jun 08 — IV 38% · EM ±5.0%Jun 09 — IV 39% · EM ±4.8%Jun 10 — IV 36% · EM ±4.3%Jun 11 — IV 28% · EM ±3.1%Jun 12 — IV 28% · EM ±2.9%Jun 15 — IV 61% · EM ±4.4%Jun 17 — IV 100% · EM ±4.2%Jun 19 — IV 42% · EM ±9.4%Jun 22 — IV 55% · EM ±11.4%Jun 23 — IV 60% · EM ±12.3%Jun 24 — IV 52% · EM ±10.3%Jun 25 — IV 51% · EM ±10.1%Jun 26 — IV 46% · EM ±8.7%Jun 29 — IV 39% · EM ±6.9%Jun 30 — IV 42% · EM ±7.3%Jul 01 — IV 38% · EM ±6.4%Jul 02 — IV 44% · EM ±7.2%Jul 03 — IV 46% · EM ±7.2%Jul 06 — IV 44% · EM ±6.1%Jul 07 — IV 55% · EM ±7.2%Jul 08 — IV 52% · EM ±6.5%Jul 09 — IV 65% · EM ±7.7%Jul 10 — IV 51% · EM ±5.6%Jul 13 — IV 61% · EM ±5.1%Jul 14 — IV 50% · EM ±3.6%Jul 15 — IV 49% · EM ±2.9%Jul 16 — IV 69% · EM ±2.9%Jul 20 — IV 60% · EM ±14.1%Jul 21 — IV 50% · EM ±11.7%Jul 22 — IV 51% · EM ±11.7%Jul 23 — IV 48% · EM ±10.9%Jul 24 — IV 50% · EM ±11.1%Jul 27 — IV 49% · EM ±10.2%Jul 28 — IV 49% · EM ±10.0%Jul 29 — IV 43% · EM ±8.7%Jul 30 — IV 47% · EM ±9.1%Jul 31 — IV 46% · EM ±8.8%Aug 03 — IV 50% · EM ±8.9%Aug 04 — IV 57% · EM ±9.8%Aug 05 — IV 58% · EM ±9.6%Aug 06 — IV 55% · EM ±8.9%Aug 07 — IV 40% · EM ±6.3%Aug 10 — IV 47% · EM ±6.5%Aug 11 — IV 39% · EM ±5.2%Aug 12 — IV 47% · EM ±5.9%Aug 13 — IV 45% · EM ±5.3%Aug 14 — IV 45% · EM ±5.0%Aug 17 — IV 60% · EM ±5.0%Aug 18 — IV 50% · EM ±3.6%Aug 19 — IV 52% · EM ±3.1%Aug 20 — IV 124% · EM ±5.2%Aug 24 — IV 50% · EM ±10.4%Aug 25 — IV 56% · EM ±11.4%Aug 26 — IV 59% · EM ±11.9%Aug 27 — IV 56% · EM ±10.9%Aug 28 — IV 55% · EM ±10.5%Aug 31 — IV 59% · EM ±10.4%Sep 01 — IV 56% · EM ±9.6%Sep 02 — IV 57% · EM ±9.5%Sep 03 — IV 63% · EM ±10.1%Sep 04 — IV 61% · EM ±9.5%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in